[{"type": "title", "data": "PED SUS buprenorphine-naloxone (Suboxone) First Day Standard Induction"}, {"type": "category", "data": "Admit/Transfer/Discharge"}, {"type": "note", "data": "Ensure PED SUS Acute Opioid Withdrawal PowerPlan has been ordered prior to completing this PowerPlan", "value": ""}, {"type": "note", "data": "Buprenorphine is an opioid and providers should be familiar with College of Physicians and Surgeons of BC Practice Standards on Safe Prescribing of Opioids and Sedatives and BC Centre for Substance Use Guidelines on Treatment of Opioid Use Disorder", "value": ""}, {"type": "note", "data": "Standard buprenorphine-naloxone induction is to be used in patients with opioid use disorder who do not meet criteria for rapid microinduction", "value": ""}, {"type": "note", "data": "To consider standard induction patients should be:  \n- 12 or more hours since last dose of short acting opioids (heroin, oxycodone, hydromorphone, etc.) \n- 24 or more hours since last dose of long acting (fentanyl patch, methadone, oxycodone controlled-release) or suspected illicit fentanyl \n- If uncertain how long to wait before initiating buprenorphine-naloxone recommend consulting addictions medicine", "value": ""}, {"type": "category", "data": "Patient Care"}, {"type": "order", "data": "Clinical Opiate Withdrawal Scale", "value": "checked"}, {"type": "sentence", "data": "First 24 hours: Assess subjective cravings or withdrawal symptoms and COWS scoring, prior to providing each dose of buprenorphine-naloxone, q30min for 1 hour after each dose (including PRN), then q2h"}, {"type": "order", "data": "Notify Treating Provider", "value": "checked"}, {"type": "sentence", "data": "Notify provider immediately if COWS score increases or patient reports worsening withdrawal after receiving buprenorphine-naloxone. Or if withdrawal symptoms are not adequately managed with medication"}, {"type": "category", "data": "Medications"}, {"type": "order", "data": "buprenorphine-naloxone 2 mg-0.5 mg tab (dosed as buprenorphine)", "value": ""}, {"type": "sentence", "data": "2 mg, sublingual, once, order duration: 24 hour, drug form: tab"}, {"type": "sentence", "data": "4 mg, sublingual, once, order duration: 24 hour, drug form: tab"}, {"type": "order", "data": "buprenorphine-naloxone 2 mg-0.5 mg tab (dosed as buprenorphine)", "value": ""}, {"type": "sentence", "data": "2 mg, sublingual, q1h, PRN other (see comment), drug form: tab"}, {"type": "sentence", "data": "4 mg, sublingual, q1h, PRN other (see comment), drug form: tab"}, {"type": "note", "data": "Provider MUST complete PED SUS buprenorphine-naloxone (Suboxone) Subsequent Days Standard Induction PowerPlan for ongoing therapy after first 24 hours", "value": ""}, {"type": "sentence", "data": "None"}, {"type": "sentence", "data": "None"}, {"type": "sentence", "data": "None"}, {"type": "sentence", "data": "None"}, {"type": "sentence", "data": "None"}, {"type": "sentence", "data": "None"}, {"type": "sentence", "data": "None"}, {"type": "category", "data": "24 hour duration"}, {"type": "sentence", "data": "None"}, {"type": "category", "data": "PRN"}, {"type": "sentence", "data": "None"}]
